Clinical trial
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's…
NCT00472849 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00472849 |
|---|---|
| Title | Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias |
| Official title | A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Richter's Transformation, Leukemia |
| Intervention type | Drug |
| Interventions | Oxaliplatin, Fludarabine, Cytarabine, Rituximab, Pegfilgrastim |
| Enrollment | 92 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | May 14, 2007 |
| Last update posted | Nov 26, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: